Beta Bionics, INC Form 4 insider transactions

Beta Bionics, Inc.'s Chief Medical Officer, Steven Jon Russell, sold 1,039 shares of common stock on June 2, 2025, to satisfy tax withholding obligations related to restricted stock unit vesting.

Beta Bionics' Chief Product Officer, Mike Mensinger, sold 1,115 shares of common stock on June 2, 2025, to satisfy tax withholding obligations related to the vesting of restricted stock units.

Beta Bionics, Inc.'s Chief Financial Officer, Stephen Feider, sold a total of 1,497 shares of common stock on June 2, 2025, to satisfy tax withholding obligations related to restricted stock unit vesting.

Sean Saint, President and CEO of Beta Bionics, Inc., sold 3,439 shares of common stock on June 2, 2025, to satisfy tax withholding obligations related to the vesting of restricted stock units.

Director Gerard J. Michel reports acquisition of 12,547 shares of Beta Bionics, Inc. via a restricted stock unit award.

Christy Jones, a director of Beta Bionics, acquired 11,247 shares of common stock through a restricted stock unit award on March 15, 2025.

Danny L. Dearen, a director at Beta Bionics, acquired 11,247 shares of common stock through a restricted stock unit award on March 15, 2025.

Director Maria Palasis acquired 11,247 shares of Beta Bionics, Inc. common stock on March 15, 2025, through a restricted stock unit award.

Director Adam Lezack reports the acquisition of 11,247 shares of Beta Bionics, Inc. common stock through a restricted stock unit award.

Director Sean Carney acquired 11,247 shares of Beta Bionics, Inc. common stock on March 15, 2025, through a restricted stock unit award.

Mark Hopman, Chief Commercial Officer of Beta Bionics, received 52,000 stock options and 35,000 restricted stock units on February 27, 2025.

Steven Jon Russell, Chief Medical Officer of Beta Bionics, Inc., reports the acquisition of stock options and restricted stock units.

Mike Mensinger, Chief Product Officer of Beta Bionics, reports acquisition of common stock and stock options.

Stephen Feider, CFO of Beta Bionics, reports the acquisition of restricted stock units and stock options.

Sean Saint, President & CEO of Beta Bionics, acquired 108,000 shares of common stock and options to purchase 163,000 shares on February 27, 2025.

Beta Bionics' Chief Medical Officer, Steven Jon Russell, acquired stock options on January 31, 2025, as detailed in a recent SEC Form 4 filing.

Beta Bionics CEO Sean Saint reported the acquisition of multiple employee stock options on January 31, 2025, as detailed in a Form 4 filing.

Maria Palasis, a director at Beta Bionics, acquired stock options for 9,137 shares of common stock on January 31, 2025.

A Beta Bionics director, Adam Lezack, acquired stock options for 9,137 shares of common stock.

Mike Mensinger, Chief Product Officer at Beta Bionics, reports multiple transactions involving common stock and derivative securities following the company's initial public offering.

A Beta Bionics director, Christy Jones, has acquired stock options for a total of 66,904 shares of common stock.

Mark Hopman, Chief Commercial Officer of Beta Bionics, was granted multiple tranches of employee stock options on January 31, 2025.

Beta Bionics' Chief Financial Officer, Stephen Feider, reported the acquisition of multiple employee stock options on January 31, 2025.

Director Sean Carney of Beta Bionics, Inc. acquired stock options on January 31, 2025, for 86,293 shares of common stock.

Wellington Hadley Harbor Aggregator IV, L.P. reports acquiring 1,000,000 shares of Beta Bionics common stock at $17 per share in a private placement, alongside the conversion of preferred stock into common stock.

Sean Saint, CEO of Beta Bionics, reports the acquisition of stock options exercisable for 467,944 shares of Class B Common Stock (later converted to Common Stock) on January 29, 2025.

Steven Jon Russell, Chief Medical Officer of Beta Bionics, Inc., reports the acquisition of stock options.

Mike Mensinger, Chief Product Officer of Beta Bionics, acquired stock options for 110,278 shares of Class B Common Stock on January 29, 2025.

Mark Hopman, Chief Commercial Officer of Beta Bionics, acquired 47,775 employee stock options on January 29, 2025.

Stephen Feider, CFO of Beta Bionics, reports the acquisition of stock options exercisable for 186,203 shares of common stock.